{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:55:38Z","timestamp":1791413738390,"version":"4.3.3"},"publisher-location":"Totowa, NJ","reference-count":103,"publisher":"Humana Press","isbn-type":[{"value":"9781627035859","type":"print"},{"value":"9781627035866","type":"electronic"}],"license":[{"start":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T00:00:00Z","timestamp":1377561600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T00:00:00Z","timestamp":1377561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-1-62703-586-6_3","type":"book-chapter","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T14:35:56Z","timestamp":1379082956000},"page":"37-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Therapeutic Human Monoclonal Antibodies in Inflammatory Diseases"],"prefix":"10.1007","author":[{"given":"Sotirios","family":"Kotsovilis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Andreakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,27]]},"reference":[{"key":"3_CR00031","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495\u2013497","journal-title":"Nature"},{"key":"3_CR00032","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","volume":"228","author":"GP Smith","year":"1985","unstructured":"Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228:1315\u20131317","journal-title":"Science"},{"key":"3_CR00033","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1246-7820(01)00210-5","volume":"9","author":"DL Siegel","year":"2002","unstructured":"Siegel DL (2002) Recombinant monoclonal antibody technology. Transfus Clin Biol 9:15\u201322","journal-title":"Transfus Clin Biol"},{"key":"3_CR00034","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/312643a0","volume":"312","author":"GL Boulianne","year":"1984","unstructured":"Boulianne GL, Hozumi N, Shulman MJ (1984) Production of functional chimaeric mouse\/human antibody. Nature 312:643\u2013646","journal-title":"Nature"},{"key":"3_CR00035","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.1073\/pnas.81.21.6851","volume":"81","author":"SL Morrison","year":"1984","unstructured":"Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81:6851\u20136855","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR00036","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/314268a0","volume":"314","author":"MS Neuberger","year":"1985","unstructured":"Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH (1985) A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature 314:268\u2013270","journal-title":"Nature"},{"key":"3_CR00037","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/348552a0","volume":"348","author":"J McCafferty","year":"1990","unstructured":"McCafferty J, Griffiths AD, Winter G, Chiswell DJ (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552\u2013554","journal-title":"Nature"},{"key":"3_CR00038","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/08830189509061738","volume":"13","author":"N Lonberg","year":"1995","unstructured":"Lonberg N, Huszar D (1995) Human antibodies from transgenic mice. Int Rev Immunol 13:65\u201393","journal-title":"Int Rev Immunol"},{"key":"3_CR00039","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0958-1669(02)00355-5","volume":"13","author":"E Andreakos","year":"2002","unstructured":"Andreakos E, Taylor PC, Feldmann M (2002) Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol 13:615\u2013620","journal-title":"Curr Opin Biotechnol"},{"key":"3_CR000310","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","volume":"334","author":"FM Brennan","year":"1989","unstructured":"Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 334:244\u2013247","journal-title":"Lancet"},{"key":"3_CR000311","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","volume":"10","author":"J Keffer","year":"1991","unstructured":"Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025\u20134031","journal-title":"EMBO J"},{"key":"3_CR000312","doi-asserted-by":"publisher","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","volume":"89","author":"RO Williams","year":"1992","unstructured":"Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784\u20139788","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR000313","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1146\/annurev.immunol.19.1.163","volume":"19","author":"M Feldmann","year":"2001","unstructured":"Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163\u2013196","journal-title":"Annu Rev Immunol"},{"key":"3_CR000314","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/nri802","volume":"2","author":"M Feldmann","year":"2002","unstructured":"Feldmann M (2002) Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2:364\u2013371","journal-title":"Nat Rev Immunol"},{"key":"3_CR000315","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M et al (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681\u20131690","journal-title":"Arthritis Rheum"},{"key":"3_CR000316","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"JM Van den Brande","year":"2003","unstructured":"Van den Brande JM, Braat H, van den Brink GR et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology 124:1774\u20131785","journal-title":"Gastroenterology"},{"key":"3_CR000317","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125\u20131127","journal-title":"Lancet"},{"key":"3_CR000318","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105\u20131110","journal-title":"Lancet"},{"key":"3_CR000319","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932\u20131939","journal-title":"Lancet"},{"key":"3_CR000320","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"3_CR000321","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/rheumatology\/34.4.334","volume":"34","author":"EC Rankin","year":"1995","unstructured":"Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, Panayi GS (1995) The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 34:334\u2013342","journal-title":"Br J Rheumatol"},{"key":"3_CR000322","first-page":"S242","volume":"39","author":"O Sander","year":"1996","unstructured":"Sander O, Rau R, van Riel P et al (1996) Neutralization of TNF by Lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: results of a European phase II trial. Arthritis Rheum 39:S242","journal-title":"Arthritis Rheum"},{"key":"3_CR000323","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337:141\u2013147","journal-title":"N Engl J Med"},{"key":"3_CR000324","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253\u2013259","journal-title":"N Engl J Med"},{"key":"3_CR000325","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1136\/ard.60.7.660","volume":"60","author":"P Barrera","year":"2001","unstructured":"Barrera P, Joosten LA, den Broeder AA, van de Putte LB, van Riel PL, van den Berg WB (2001) Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 60:660\u2013669","journal-title":"Ann Rheum Dis"},{"key":"3_CR000326","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/rheumatology\/41.10.1133","volume":"41","author":"EH Choy","year":"2002","unstructured":"Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA (2002) Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41:1133\u20131137","journal-title":"Rheumatology (Oxford)"},{"key":"3_CR000327","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"3_CR000328","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15140","volume":"15","author":"K Malottki","year":"2011","unstructured":"Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF (2011) Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 15:1\u2013278","journal-title":"Health Technol Assess"},{"key":"3_CR000329","first-page":"96","volume":"29","author":"A R\u00e9my","year":"2011","unstructured":"R\u00e9my A, Avouac J, Gossec L, Combe B (2011) Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 29:96\u2013103","journal-title":"Clin Exp Rheumatol"},{"key":"3_CR000330","doi-asserted-by":"crossref","unstructured":"Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, G\u00e1lvez Mu\u00f1oz JG, Saiz Cuenca ES, Fry-Smith A (2011) Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev CD007649","DOI":"10.1002\/14651858.CD007649.pub2"},{"key":"3_CR000331","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3899\/jrheum.100665","volume":"38","author":"R Launois","year":"2011","unstructured":"Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B (2011) Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 38:835\u2013845","journal-title":"J Rheumatol"},{"key":"3_CR000332","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1136\/ard.2010.132134","volume":"70","author":"C Salliot","year":"2011","unstructured":"Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70:266\u2013271","journal-title":"Ann Rheum Dis"},{"key":"3_CR000333","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/art.1780390212","volume":"39","author":"BE Drevlow","year":"1996","unstructured":"Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, Landay A, Moreland LW, Pope RM (1996) Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 39:257\u2013265","journal-title":"Arthritis Rheum"},{"key":"3_CR000334","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P","volume":"43","author":"Y Jiang","year":"2000","unstructured":"Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43:1001\u20131009","journal-title":"Arthritis Rheum"},{"key":"3_CR000335","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10141","volume":"46","author":"S Cohen","year":"2002","unstructured":"Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, Kremer J, Bear MB, Rich WJ, McCabe D (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:614\u2013624","journal-title":"Arthritis Rheum"},{"key":"3_CR000336","first-page":"259","volume":"20","author":"D Wendling","year":"1993","unstructured":"Wendling D, Racadot E, Wijdenes J (1993) Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20:259\u2013262","journal-title":"J Rheumatol"},{"key":"3_CR000337","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00832010","volume":"20","author":"K Yoshizaki","year":"1998","unstructured":"Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T (1998) Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. Springer Semin Immunopathol 20:247\u2013259","journal-title":"Springer Semin Immunopathol"},{"key":"3_CR000338","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/art.1780370703","volume":"37","author":"AF Kavanaugh","year":"1994","unstructured":"Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE (1994) Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 37:992\u2013999","journal-title":"Arthritis Rheum"},{"key":"3_CR000339","first-page":"1338","volume":"23","author":"AF Kavanaugh","year":"1996","unstructured":"Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE (1996) A phase I\/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 23:1338\u20131344","journal-title":"J Rheumatol"},{"key":"3_CR000340","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/art.1780400511","volume":"40","author":"AF Kavanaugh","year":"1997","unstructured":"Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE (1997) Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 40:849\u2013853","journal-title":"Arthritis Rheum"},{"key":"3_CR000341","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/ard.2005.048371","volume":"65","author":"RM Fleischmann","year":"2006","unstructured":"Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, Modafferi D, Zhou L, Bell D, Appleton B (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65:1006\u20131012","journal-title":"Ann Rheum Dis"},{"key":"3_CR000342","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.clinthera.2012.02.014","volume":"34","author":"I Navarro-Mill\u00e1n","year":"2012","unstructured":"Navarro-Mill\u00e1n I, Singh JA, Curtis JR (2012) Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clin Ther 34:788\u2013802","journal-title":"Clin Ther"},{"key":"3_CR000343","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s10067-011-1827-x","volume":"30","author":"T Gout","year":"2011","unstructured":"Gout T, Ost\u00f6r AJ, Nisar MK (2011) Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 30:1471\u20131474","journal-title":"Clin Rheumatol"},{"key":"3_CR000344","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3899\/jrheum.100717","volume":"38","author":"JA Singh","year":"2011","unstructured":"Singh JA, Beg S, Lopez-Olivo MA (2011) Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 38:10\u201320","journal-title":"J Rheumatol"},{"key":"3_CR000345","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","volume":"50","author":"L Campbell","year":"2011","unstructured":"Campbell L, Chen C, Bhagat SS, Parker RA, \u00d6st\u00f6r AJ (2011) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 50:552\u2013562","journal-title":"Rheumatology (Oxford)"},{"key":"3_CR000346","doi-asserted-by":"crossref","unstructured":"Shaw T, Quan J, Totoritis MC (2003) B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 62(suppl 2):ii55\u2013ii59","DOI":"10.1136\/ard.62.suppl_2.ii55"},{"key":"3_CR000347","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3pez AJ, White CA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood 90:2188\u20132195","journal-title":"Blood"},{"key":"3_CR000348","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1523-5394.1998.006003195.x","volume":"6","author":"SD Scott","year":"1998","unstructured":"Scott SD (1998) Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin\u2019s lymphoma. Cancer Pract 6:195\u2013197","journal-title":"Cancer Pract"},{"key":"3_CR000349","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"MH Buch","year":"2011","unstructured":"Buch MH, Smolen JS, Betteridge N et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909\u2013920","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"3_CR000350","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","volume":"13","author":"PP Tak","year":"2011","unstructured":"Tak PP, Kalden JR (2011) Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther 13(Suppl 1):S5","journal-title":"Arthritis Res Ther"},{"key":"3_CR000351","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1093\/rheumatology\/ker106a","volume":"50","author":"M Bukhari","year":"2011","unstructured":"Bukhari M, Abernethy R, Deighton C et al (2011) BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50:2311\u20132313","journal-title":"Rheumatology (Oxford)"},{"key":"3_CR000352","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/bcr276","volume":"3","author":"SA Eccles","year":"2001","unstructured":"Eccles SA (2001) Monoclonal antibodies targeting cancer: \u201cmagic bullets\u201d or just the trigger? Breast Cancer Res 3:86\u201390","journal-title":"Breast Cancer Res"},{"key":"3_CR000353","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1365-3083.1992.tb03102.x","volume":"36","author":"EH Choy","year":"1992","unstructured":"Choy EH, Chikanza IC, Kingsley GH, Corrigall V, Panayi GS (1992) Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand J Immunol 36:291\u2013298","journal-title":"Scand J Immunol"},{"key":"3_CR000354","first-page":"1348","volume":"19","author":"BW Kirkham","year":"1992","unstructured":"Kirkham BW, Thien F, Pelton BK, Pitzalis C, Amlot P, Denman AM, Panayi GS (1992) Chimeric CD7 monoclonal antibody therapy in rheumatoid arthritis. J Rheumatol 19:1348\u20131352","journal-title":"J Rheumatol"},{"key":"3_CR000355","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/art.1780390705","volume":"39","author":"NJ Olsen","year":"1996","unstructured":"Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, St Clair EW, Matteson EL, Gold KN, Cannon GW, Jackson CG, McCune WJ, Fox DA, Nelson B, Lorenz T, Strand V (1996) A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum 39:1102\u20131108","journal-title":"Arthritis Rheum"},{"key":"3_CR000356","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","volume":"35","author":"JD Isaacs","year":"1996","unstructured":"Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St Clair EW, Schnitzer TJ, Johnston JM (1996) CAMPATH-1H in rheumatoid arthritis\u2014an intravenous dose-ranging study. Br J Rheumatol 35:231\u2013240","journal-title":"Br J Rheumatol"},{"key":"3_CR000357","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/rheumatology\/39.10.1139","volume":"39","author":"EH Choy","year":"2000","unstructured":"Choy EH, Connolly DJ, Rapson N, Jeal S, Brown JC, Kingsley GH, Panayi GS, Johnston JM (2000) Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients. Rheumatology (Oxford) 39:1139\u20131146","journal-title":"Rheumatology (Oxford)"},{"key":"3_CR000358","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/ard.58.6.342","volume":"58","author":"DJ Veale","year":"1999","unstructured":"Veale DJ, Reece RJ, Parsons W, Radjenovic A, O\u2019Connor PJ, Orgles CS, Berry E, Ridgway JP, Mason U, Boylston AW, Gibbon W, Emery P (1999) Intra-articular primatised anti-CD4: efficacy in resistant rheumatoid knees. A study of combined arthroscopy, magnetic resonance imaging, and histology. Ann Rheum Dis 58:342\u2013349","journal-title":"Ann Rheum Dis"},{"key":"3_CR000359","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med 337:1029\u20131035","journal-title":"N Engl J Med"},{"key":"3_CR000360","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0016-5085(99)70224-6","volume":"116","author":"FJ Baert","year":"1999","unstructured":"Baert FJ, D\u2019Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn\u2019s ileocolitis. Gastroenterology 116:22\u201328","journal-title":"Gastroenterology"},{"key":"3_CR000361","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","volume":"116","author":"G D\u2019Haens","year":"1999","unstructured":"D\u2019Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn\u2019s disease: A European multicenter trial. Gastroenterology 116:1029\u20131034","journal-title":"Gastroenterology"},{"key":"3_CR000362","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med 340:1398\u20131405","journal-title":"N Engl J Med"},{"key":"3_CR000363","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0016-5085(99)70332-X","volume":"117","author":"P Rutgeerts","year":"1999","unstructured":"Rutgeerts P, D\u2019Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn\u2019s disease. Gastroenterology 117:761\u2013769","journal-title":"Gastroenterology"},{"key":"3_CR000364","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, ACCENT I Study Group (2002) Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet 359:1541\u20131549","journal-title":"Lancet"},{"key":"3_CR000365","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ (2004) Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med 350:876\u2013885","journal-title":"N Engl J Med"},{"key":"3_CR000366","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/bega.2003.0361","volume":"17","author":"SB Hanauer","year":"2003","unstructured":"Hanauer SB (2003) Crohn\u2019s disease: step up or top down therapy. Best Pract Res Clin Gastroenterol 17:131\u2013137","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"3_CR000367","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1111\/j.1572-0241.2001.04705.x","volume":"96","author":"G D\u2019Haens","year":"2001","unstructured":"D\u2019Haens G, Swijsen C, Noman M, Lemmens L, Ceuppens J, Agbahiwe H, Geboes K, Rutgeerts P (2001) Etanercept in the treatment of active refractory Crohn\u2019s disease: a single-center pilot trial. Am J Gastroenterol 96:2564\u20132568","journal-title":"Am J Gastroenterol"},{"key":"3_CR000368","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR (2001) Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121:1088\u20131094","journal-title":"Gastroenterology"},{"key":"3_CR000369","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1053\/gast.2001.24042","volume":"120","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR, CDP571 Crohn\u2019s Disease Study Group (2001) An engineered human antibody to TNF (CDP571) for active Crohn\u2019s disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120:1330\u20131338","journal-title":"Gastroenterology"},{"key":"3_CR000370","first-page":"840","volume":"350","author":"TS Kupper","year":"2004","unstructured":"Kupper TS (2004) Etanercept for Crohn\u2019s disease. N Engl J Med 350:840","journal-title":"N Engl J Med"},{"key":"3_CR000371","doi-asserted-by":"crossref","unstructured":"Akobeng AK, Zachos M (2004) Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev CD003574","DOI":"10.1002\/14651858.CD003574.pub2"},{"key":"3_CR000372","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1097\/MEG.0b013e32834b9544","volume":"23","author":"Z Lin","year":"2011","unstructured":"Lin Z, Bai Y, Zheng P (2011) Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn\u2019s disease. Eur J Gastroenterol Hepatol 23:1100\u20131110","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3_CR000373","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1751-2980.2011.00493.x","volume":"12","author":"ML Huang","year":"2011","unstructured":"Huang ML, Ran ZH, Shen J, Li XB, Xu XT, Xiao SD (2011) Efficacy and safety of adalimumab in Crohn\u2019s disease: meta-analysis of placebo-controlled trials. J Dig Dis 12:165\u2013172","journal-title":"J Dig Dis"},{"key":"3_CR000374","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/ajg.2011.73","volume":"106","author":"AC Ford","year":"2011","unstructured":"Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106:644\u2013659","journal-title":"Am J Gastroenterol"},{"key":"3_CR000375","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/j.1365-2036.2011.04598.x","volume":"33","author":"S Danese","year":"2011","unstructured":"Danese S, Colombel JF, Reinisch W, Rutgeerts PJ (2011) Review article: infliximab for Crohn\u2019s disease treatment\u2013shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther 33:857\u2013869","journal-title":"Aliment Pharmacol Ther"},{"key":"3_CR000376","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15060","volume":"15","author":"J Dretzke","year":"2011","unstructured":"Dretzke J, Edlin R, Round J, Connock M, Hulme C, Czeczot J, Fry-Smith A, McCabe C, Meads C (2011) A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-\u03b1) inhibitors, adalimumab and infliximab, for Crohn\u2019s disease. Health Technol Assess 15:1\u2013244","journal-title":"Health Technol Assess"},{"key":"3_CR000377","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ibd.21341","volume":"17","author":"EV Loftus Jr","year":"2011","unstructured":"Loftus EV Jr, Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J (2011) Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn\u2019s disease. Inflamm Bowel Dis 17:127\u2013140","journal-title":"Inflamm Bowel Dis"},{"key":"3_CR000378","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2174\/1381612023394737","volume":"8","author":"DY Jackson","year":"2002","unstructured":"Jackson DY (2002) Alpha 4 integrin antagonists. Curr Pharm Des 8:1229\u20131253","journal-title":"Curr Pharm Des"},{"key":"3_CR000379","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462\u20132476","journal-title":"N Engl J Med"},{"key":"3_CR000380","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00296-009-0973-9","volume":"29","author":"L Goh","year":"2009","unstructured":"Goh L, Samanta A (2009) A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 29:1123\u20131135","journal-title":"Rheumatol Int"},{"key":"3_CR000381","unstructured":"van den Bosch F, Beaten D, Kruithof E, DeKeyser F, Mielants H, Veys EM (2001) Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha. Ann Rheum Dis 60(suppl 3):iii33\u2013iii36"},{"key":"3_CR000382","first-page":"118","volume":"29","author":"J Brandt","year":"2002","unstructured":"Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2002) Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29:118\u2013122","journal-title":"J Rheumatol"},{"key":"3_CR000383","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/ard.61.3.207","volume":"61","author":"E Kruithof","year":"2002","unstructured":"Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM (2002) Repeated infusions of infliximab, a chimeric anti-TNF\u03b1 monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61:207\u2013212","journal-title":"Ann Rheum Dis"},{"key":"3_CR000384","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, S\u00f6rensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187\u20131193","journal-title":"Lancet"},{"key":"3_CR000385","doi-asserted-by":"publisher","first-page":"S403","DOI":"10.1002\/1529-0131(200004)43:4<930::AID-ANR27>3.0.CO;2-A","volume":"43","author":"JD Gorman","year":"2000","unstructured":"Gorman JD, Sack KE, Davis JC (2000) Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebocontrolled study. Arthritis Rheum 43:S403","journal-title":"Arthritis Rheum"},{"key":"3_CR000386","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, Stein LD, Gedalia A, Ilowite NT, Wallace CA, Whitmore J, Finck BK (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763\u2013769","journal-title":"N Engl J Med"},{"key":"3_CR000387","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/ard.61.2.171","volume":"61","author":"DA Kietz","year":"2002","unstructured":"Kietz DA, Pepmueller PH, Moore TL (2002) Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. Ann Rheum Dis 61:171\u2013173","journal-title":"Ann Rheum Dis"},{"key":"3_CR000388","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.semarthrit.2010.06.003","volume":"40","author":"J De La Mata","year":"2011","unstructured":"De La Mata J, Maese J, Martinez JA, Rosario P, Loza E (2011) Current evidence of the management of undifferentiated spondyloarthritis: a systematic literature review. Semin Arthritis Rheum 40:421\u2013429","journal-title":"Semin Arthritis Rheum"},{"key":"3_CR000389","unstructured":"Chaitow J, De Benedetti F, Brunner H et al (2010) Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER Trial. Ann Rheum Dis 69(suppl 3):146"},{"key":"3_CR000390","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"U Chaudhari","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842\u20131847","journal-title":"Lancet"},{"key":"3_CR000391","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1136\/ard.61.4.298","volume":"61","author":"PJ Mease","year":"2002","unstructured":"Mease PJ (2002) Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61:298\u2013304","journal-title":"Ann Rheum Dis"},{"key":"3_CR000392","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356:385\u2013390","journal-title":"Lancet"},{"key":"3_CR000393","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.jaad.2010.09.734","volume":"64","author":"ED Dommasch","year":"2011","unstructured":"Dommasch ED, Abuabara K, Shin DB, Nguyen J, Troxel AB, Gelfand JM (2011) The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol 64:1035\u20131050","journal-title":"J Am Acad Dermatol"},{"key":"3_CR000394","doi-asserted-by":"crossref","unstructured":"Rodgers M., Epstein D., Bojke L., et al. (2011) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 15:i\u2013xxi, 1\u2013329","DOI":"10.3310\/hta15100"},{"key":"3_CR000395","first-page":"883","volume":"35","author":"AA Saad","year":"2008","unstructured":"Saad AA, Symmons DP, Noyce PR, Ashcroft DM (2008) Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 35:883\u2013890","journal-title":"J Rheumatol"},{"key":"3_CR000396","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.jbspin.2007.10.003","volume":"74","author":"T Pham","year":"2007","unstructured":"Pham T, Fautrel B, Dernis E et al (2007) Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 74:638\u2013646","journal-title":"Joint Bone Spine"},{"key":"3_CR000397","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","volume":"59","author":"SD Doherty","year":"2008","unstructured":"Doherty SD, van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, Foundation NP (2008) National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 59:209\u2013217","journal-title":"J Am Acad Dermatol"},{"key":"3_CR000398","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJM200107263450403","volume":"345","author":"CN Ellis","year":"2001","unstructured":"Ellis CN, Krueger GG, Alefacept Clinical Study Group (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248\u2013255","journal-title":"N Engl J Med"},{"key":"3_CR000399","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","volume":"44","author":"JH Stone","year":"2001","unstructured":"Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS (2001) Etanercept combined with conventional treatment in Wegener\u2019s granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 44:1149\u20131154","journal-title":"Arthritis Rheum"},{"key":"3_CR0003100","unstructured":"Ellman MH, MacDonald PA, Hayes FA (2000) Etanercept as treatment for diffuse scleroderma: a pilot study. Arthritis Rheum 43(Suppl.): S392"},{"key":"3_CR0003101","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","volume":"44","author":"A Reiff","year":"2001","unstructured":"Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44:1411\u20131415","journal-title":"Arthritis Rheum"},{"key":"3_CR0003102","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","volume":"96","author":"RB Nussenblatt","year":"1999","unstructured":"Nussenblatt RB, Fortin E, Schiffman R, Rizzo L, Smith J, van Veldhuisen P, Sran P, Yaffe A, Goldman CK, Waldmann TA, Whitcup SM (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial. Proc Natl Acad Sci USA 96:7462\u20137466","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR0003103","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.53.3.466","volume":"53","author":"N Tubridy","year":"1999","unstructured":"Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, Young C, Moseley IF, MacManus DG, Donoghue S, Miller DH (1999) The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 53:466\u2013472","journal-title":"Neurology"}],"container-title":["Methods in Molecular Biology","Human Monoclonal Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-62703-586-6_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T20:15:17Z","timestamp":1649794517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-62703-586-6_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,27]]},"ISBN":["9781627035859","9781627035866"],"references-count":103,"URL":"https:\/\/doi.org\/10.1007\/978-1-62703-586-6_3","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,27]]},"assertion":[{"value":"27 August 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}